Author

Cesare Casadei

SWITCHING FROM ADALIMUMAB ORIGINATOR TO ABP 501 BIOSIMILAR: A MULTICENTRIC NORTH ITALIAN STUDY
SWITCHING FROM ADALIMUMAB ORIGINATOR TO ABP 501 BIOSIMILAR: A MULTICENTRIC NORTH ITALIAN STUDY

Cesare Casadei  et al.

THE ANTI IL-23/IL-12 AGENT USTEKINUMAB IS AN EFFECTIVE AND SAFE INDUCTION THERAPY IN PATIENTS WITH CROHN'S DISEASE REFRACTORY OR INTOLERANT TO ANTI-TNF: A MULTICENTRE ITALIAN STUDY
THE ANTI IL-23/IL-12 AGENT USTEKINUMAB IS AN EFFECTIVE AND SAFE INDUCTION THERAPY IN PATIENTS WITH CROHN'S DISEASE REFRACTORY OR INTOLERANT TO ANTI-TNF: A MULTICENTRE ITALIAN STUDY

Cesare Casadei  et al.

Item 1 - 2 / 2
1